Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Cyclosporine NEORAL Oral Solution Novartis is an
2021-05-07

Cyclosporine (NEORAL® Oral Solution, Novartis) is an immunosuppressant widely used in organ transplantation and many other clinical conditions [12]. It undergoes extensive hepatic and intestinal biotransformation mainly via the metabolizing enzyme, CYP3A4 [[12], [13], [14], [15]]. Considering the na
-
br Results br Discussion The ubiquitin system has in
2021-05-07

Results Discussion The ubiquitin system has in recent years become an exciting area for drug discovery (Cohen and Tcherpakov, 2010), as multiple enzymatic steps within the ubiquitylation process are druggable. The potential of targeting the ubiquitin-proteasome pathway was first demonstrated i
-
Ginsenoside Re lysine mixture had increased
2021-05-07

Ginsenoside Re-lysine mixture had increased anticancer effects upon heat processing by regulating Bcl-2 and Bax (Yamabe et al., 2013). Ginsenoside Re (20mg/kg) inhibited NF-κB activation by inhibiting LPS binding to TLR4 on macrophages in TNBS-treated mice (Lee, Hyam, Jang, Han, & Kim, 2012). The ch
-
br Conflict of interest br Acknowledgements
2021-05-07

Conflict of interest Acknowledgements The authors are grateful to laboratory technician Kristina Andersson for expert technical assistance. The authors acknowledge the Swedish Research Council (Grant no. 6834), Region Skåne and Faculty of Medicine, Lund University, for financial support. In
-
However a two receptor model presents a mystery
2021-05-07

However, a two-receptor model presents a mystery of how MBns know whether they are receiving an acquisition or forgetting signal from the PPL1 DAns. The most attractive explanation for this is that the two receptors might have different signaling properties and mobilize distinct signaling cascades.
-
A range of inhibitors were therefore synthesized containing
2021-05-07

A range of inhibitors were therefore synthesized containing either carboxylic SC75741 or ester functionality at the ‘tail’ group as well as variations in the ‘head.’ These were assayed in vitro using the DCIP assay for binding affinity against and human DHODH at 50μM, respectively (). Analysis of
-
P falciparum DHFR TS is a particularly important enzyme beca
2021-05-07

P. falciparum DHFR-TS is a particularly important enzyme, because it is from the protozoan species that is associated with most malaria infections. Since this enzyme is responsible for catalyzing sequential reactions in the thymidylate cycle, its inhibition slows malarial dTMP production and therefo
-
For radiochemotherapy it is well
2021-05-06

For radiochemotherapy, it is well known that mitotic cell death and apoptosis present the major cell death modes. More recently, autophagy-dependent cell death has been described to occur upon radiochemotherapy (Daido et al., 2005, Song et al., 2017). This form of regulated cell death depends on com
-
Additionally of outmost important is the location
2021-05-06

Additionally, of outmost important is the location of the different CpG islands in relation to the transcription starting site (TSS) of the promoter as well as their interaction with transcription activators or repressors. It has been shown that methylation at the downstream region of the TSS in the
-
br Acknowledgments This study was supported by grants from t
2021-05-06

Acknowledgments This study was supported by grants from the Spanish Ministry of Economy and CompetitivenessPI10/00387, PI12/01087, PI12/01703, IPT-2011-0817-010000, and RIC Red de Investigación Cardiovascular (RIC)RD12/0042/0055. RIC is an initiative of Instituto de Salud Carlos III (ISCIII), Spa
-
br Discussion We are reporting a cryptic insertion
2021-05-06

Discussion We are reporting a cryptic insertion of chromosome 22 material (EWS) to the long arm of chromosome 11 (11q24, FLI-1) recognizable by FISH in GSK2334470 exhibiting trisomy 8 as the sole cytogenetic anomaly. In ES and PNET tumors, trisomy 8 is the most common secondary abnormality [6].
-
Fujimoto et al pointed out
2021-05-06

Fujimoto et al. pointed out that RPN2 knockout alleviated the resistance of GC Caspase-8, human recombinant protein mg (MKN74 and KATO III) to docetaxel and DDP [23]. Yuan et al. demonstrated that the depletion of RPN2 resulted in the reduction in resistance of GC cells to drugs such as irinotecan,
-
Molecular docking study of compound was performed
2021-05-06

Molecular docking study of Phosphatase Inhibitor Cocktail 1 (100X in DMSO) was performed using the Schrödinger Small-Molecule Drug Discovery Suite taking advantage of known X-ray crystal structures of activated EPAC2 protein. The model shows that compound occupies the CBD of EPAC2 and forms hydrogen
-
Our results from neutropenic mice infected with both
2021-05-06

Our results from neutropenic mice infected with both fungal strains revealed that the inflammatory process was more severe 72hours post-infection (Fig. 4). Angioinvasion was mainly observed 48hours after infection for both strains. Transformation of A. fumigatus conidia into hyphae in immunocompeten
-
The AURA trial was a phase I II study
2021-05-06

The AURA trial was a phase I/II study evaluating the safety, tolerability and activity of Osimertinib in patients with EGFR-mutated NSCLC progressing after a previous EGFR TKI. The phase I component of the study included a dose escalation part (Osimertinib 20mg to 240mg), using a rolling six design,
16389 records 700/1093 page Previous Next First page 上5页 696697698699700 下5页 Last page